Retargeting Lentiviruses via SpyCatcher-SpyTag Chemistry for Gene Delivery into Specific Cell Types

Nagarjun Kasaraneni,a Ana M. Chamoun-Emanuelli,a Gus Wright,b Zhilei Chena

Department of Microbial Pathogenesis and Immunology, Texas A&M University Health Science Center, College Station, Texas, USAa; Department of Veterinary Pathobiology, Texas A&M University, College Station, Texas, USAb

ABSTRACT We report a simple strategy for the creation of lentiviral vectors specific to any desired target cells. SpyTag is inserted into an engineered Sindbis virus envelope protein and displayed on the lentivirus surface to create Sindbis virus-SpyTag pseudoparticles (Sind-SpyTag-pp). The SpyTag serves as the covalent anchoring site for a target-cell-specific cell-binding protein (CBP) that is fused to a truncated SpyCatcher (SpyCatcherΔ). Target-cell-specific lentiviruses are created by mixing the Sind-SpyTag-pp and CBP-SpyCatcherΔ in vitro. We first used a HER2-binding designed ankyrin repeat protein (DARPin.9.26) as the model CBP. The DARPin-conjugated lentivirus transduced HER2+ SKOV3 cells with an infectious titer of 5.2 × 10⁵ IU/ml, >500-fold higher than the unfunctionalized “naked” virions (≤10⁴ IU/ml). The ability of the DARPin-conjugated lentivirus to transduce HER2+ cells correlated with the surface expression level of HER2. Furthermore, these lentiviruses preferentially transduced HER2+ cells in cocultures containing HER2+ and HER2− cells. To enable the use of commercially available monoclonal antibodies (MAbs) as the CBP, we developed a convenient click chemistry-based approach to conjugate MAb-derived Fab fragments to a variant SpyCatcherΔ protein containing a nonnatural amino acid, 4-azido-L-phenylalanine (AzF). Using the HER2-binding trastuzumab as a model cell-specific MAb, we created Fab-conjugated lentiviral vectors that transduced HER2+ SKOV3 cells with an infectious titer of 2.8 × 10⁵ IU/ml, on par with the result achieved using the DARPin-SpyCatcherΔ fusion protein. The ability to create cell-specific lentiviral vectors through chemical conjugation of a CBP should make this approach generalizable to any antibody, giving it broad utility for a wide range of research and clinical applications.

IMPORTANCE Lentiviral vectors hold great potential in gene therapy. However, it remains a major hurdle to robustly engineer cell-specific lentiviral vectors. This article reports a simple and effective strategy to functionalize lentiviral vectors with cell-binding proteins, thus retargeting these viruses to cells expressing the binding partner of the CBP. The CBP is genetically or chemically linked to the SpyCatcher. The SpyTag is displayed on the virion surface as a fusion to an engineered Sindbis virus envelope protein and is used as the anchorage site for SpyCatcher-linked CBP. Using this strategy, we created lentiviral vectors highly infectious toward HER2+ cancer cells. The ability to rapidly create cell-specific lentiviral vectors targeting a wide range of cell types should accelerate the development of custom lentiviral vectors for many research and clinical applications.

KEYWORDS antibody, breast cancer, gene therapy, redirect, specificity

Lentiviral vectors can infect both dividing and nondividing cells and integrate their transgene into the host cell’s chromosome for sustained gene expression, a favorable trait for gene therapy of many chronic and malignant diseases (1, 2). Lentivirus-
based gene therapy vector Kymriah (CTL019) (3), which generates CD19 receptor-specific CAR T cells, was recently approved by the FDA for treatment of a form of acute lymphoblastic leukemia (ALL) (3). Like most current lentivirus-based gene therapies, Kymriah viruses are lentiviruses pseudotyped with vesicular stomatitis virus glycoprotein pseudoparticles (VSV-Gpp) and are delivered to patient cells \textit{ex vivo} as VSV-Gpp promiscuously transduce a wide range of cells (4) and lack the necessary specificity needed for \textit{in vivo} application. Development of robust cell-specific lentiviral vectors suitable for \textit{in vivo} applications remains a major hurdle in gene therapy. To date, multiple strategies have been explored to create cell-type-specific lentiviral vectors. For example, lentiviral vectors have been pseudotyped with envelope proteins from viruses that have a natural tropism for the target cell type (5–7). Not surprisingly, most of the clinically relevant cell types (e.g., HER2$^+$ cancer cells) cannot be specifically targeted by natural viral envelope proteins, and as a result, this approach is extremely limited for gene therapy applications. In addition, efficient pseudotyping often requires extensive protein engineering of the cytoplasmic region of the viral envelope protein (5, 8–10), limiting the applicability of this strategy. Adapter molecules that function as bridges between the cell-binding molecule and the viral vector have achieved some success. However, the association of adapter molecules with the viral vectors is noncovalent (11, 12), limiting their shelf life. Another strategy is to reengineer the specificity of lentiviruses through genetic fusion of a cell-binding protein to a viral envelope protein (13). Using this strategy, Bender et al. created a panel of lentiviral vectors specific to different cell types (9). Unfortunately, efficient transduction requires structural cooperation or “surface compatibility” between the cell-binding protein and the viral envelope protein, limiting the types of cells accessible for gene delivery using this approach (14).

Previously, our group developed a strategy to reengineer the cell-type specificity of lentiviruses which employed a splicing-deficient DnaE intein from \textit{Nostoc punctiforme} (Npu) (15). The splicing-deficient C-intein fragment, NpuC* (16), was inserted into an extracellular loop of an engineered binding-deficient fusion-competent (“blinded”) Sindbis virus E2 envelope protein between residues 71 and 74 (17, 18), while the N-intein fragment, NpuN, was fused to a cell-binding protein (CBP). The noncovalent interaction between the N- and C-intein fragments enabled the virions to be functionalized with the CBP and thereby be directed to the desired cell type expressing the binding partner of CBP. Unfortunately, despite the low nanomolar affinity between the two fragments of the DnaE intein, the conjugation between the virus and the CBP was observed to be unstable, likely due to the noncovalent nature of the N- and C-intein interaction, hampering the utility of these reprogrammed viral vectors for \textit{in vivo} applications.

In this study, we employ an isopeptide bond-forming protein-peptide pair, SpyTag and SpyCatcher, from the CnaB2 domain of the fibronectin binding protein in \textit{Streptococcus pyogenes} (19–22) to anchor a cell surface marker-specific protein to the lentiviral surface. Although the exact function remains unknown (23), the CnaB2 domain contains a natural intramolecular isopeptide bond formed spontaneously between two adjacent residues, Lys31 and Asp117, located in two neighboring $\beta$-strands. Howarth and coworkers split the $\beta$-strand harboring Asp117 from CnaB and named it SpyTag and renamed the remaining CnaB SpyCatcher (20). SpyCatcher and SpyTag spontaneously reconstitute the fold of CnaB and rapidly form an intermolecular isopeptide bond at mild temperatures without the need for extraneous chemical reagents or catalysts (21, 24, 25). This reaction has been used in many applications, including the synthesis of an unusual nonlinear elastin-like protein polymer (24), the formation of protein hydrogels (26, 27), and the creation of multivalent antigen-presenting vaccines from virus-like particles (28). The SpyTag was used to replace NpuC* in our earlier Sindbis virus E2 envelope protein-NpuC* construct (15) to form Sind-SpyTag, and this protein was displayed on the lentivirus surface. A truncated SpyCatcher, SpyCatcher$\Delta$, which displays significantly reduced nonspecific cell-binding effects (see Fig. S1 in the supplemental material), was genetically fused or chemically conjugated to a CBP to form CBP-SpyCatcher$\Delta$. Coincubation of lentiviruses pseu-
dotyped with Sind-SpyTag (Sind-SpyTag-pp) with CBP-SpyCatcherΔ yields lentiviruses covalently functionalized with the CBP, conferring these virions with specificity toward cells that express the binding partner of the conjugated CBP on their surface (Fig. 1).

Using a HER2-binding designed ankyrin repeat protein, DARPin.9.26 (29) (referred to as DARPin in this work), and a Fab fragment derived from the HER2-specific monoclonal antibody (MAb) trastuzumab (Herceptin) (30) as the model CBPs, we created lentiviral vectors that transduced HER2+/H11001 cells with high efficiency and specificity. DARPin was genetically fused to SpyCatcherΔ, while Fab was chemically conjugated to SpyCatcherΔ via copper-free click chemistry. Moreover, the infectivity of our SpyTag-SpyCatcherΔ virions is not negatively impacted by human serum complement, and given the covalent nature of the isopeptide bond formed between SpyCatcher and SpyTag, the association of CBP with the virions should be stable and nonreversible during circulation. These properties should render these functionalized virions appealing for in vivo applications.

RESULTS

Specificity reengineering of lentivirus with DARPin-SpyCatcherΔ. We present a simple strategy for retargeting lentiviral vectors to deliver their genetic cargo to desired cell types. This strategy employs a peptide pair, SpyCatcher and SpyTag, for covalent functionalization of the lentiviral vectors with a cell-binding protein (CBP), thus directing the vectors to specifically transduce cells displaying the binding partner of the CBP. SpyTag was inserted into an exposed extracellular loop on Sindbis virus E2 envelope protein between residues 71 and 74 to form Sind-SpyTag (Fig. 1). DARPin.9.26 (referred to as DARPin in this work), which binds domains I to III of HER2 with a $K_d$ (dissociation constant) of 1.4 nM (31), was used as the model CBP and was fused to the SpyCatcherΔ protein, which lacks 21 residues at the N terminus and 14 residues at the C terminus of the original SpyCatcher protein (22), to form DARPin-SpyCatcherΔ. The truncated SpyCatcherΔ protein was used because full-length SpyCatcher showed significant nonspecific interaction with an unknown cell surface receptor, causing significant background transduction of virions functionalized with SpyCatcher alone (Fig. S1).

We first evaluated the ability of SpyCatcherΔ to form an isopeptide bond with SpyTag. Purified DARPin-SpyCatcherΔ (29.2 kDa) was incubated with SUMO-SpyTag (14 kDa) at a 1:1 molar ratio for 1 to 180 min at room temperature and analyzed via SDS-PAGE. Formation of an isopeptide bond between SpyCatcherΔ and SUMO-SpyTag yields a new protein product of ~34 kDa. As shown in Fig. 2, >90% reaction completion was achieved within the first minute of incubation, indicating that the truncated SpyCatcherΔ retains the ability to react efficiently with SpyTag.

In order for the chimeric Sind-SpyTag envelope protein to be incorporated on virions, it must first be displayed on the host mammalian cell surface. To evaluate cell
surface expression of Sind-SpyTag, 293T cells were transiently transfected with plasmid encoding Sind-SpyTag or Sind-C* (15) (positive control). The presence of the chimeric proteins (Fig. 3A, which contained an N-terminal 3× Flag tag) on the cell surface, was analyzed by flow cytometry 48 h posttransfection after staining the cells with anti-Flag antibody and the appropriate Dylight 488-conjugated secondary antibody. As shown in Fig. 3B, Sind-SpyTag protein was displayed on the cell surface with similar efficiency to the positive control Sind-C*.

![FIG 2](image1.png)

**FIG 2** In vitro activity of DARPin-SpyCatcherΔ and SpyTag. One-step immobilized-metal affinity chromatography (IMAC)-purified SUMO-SpyTag (21) (20 μM) and DARPin-SpyCatcherΔ or -SpyCatcher (20 μM) were mixed in Dulbecco’s phosphate-buffered saline (DPBS) and incubated at room temperature. Samples were taken at different time points and analyzed on a 12% SDS-PAGE gel after Coomassie staining. The arrow indicates the product formed by the SpyTag-SpyCatcherΔ reaction.

![FIG 3](image2.png)

**FIG 3** (A) Schematic representation of chimeric Sindbis envelope protein used in this study. Both Sind-C* and Sind-SpyTag contain a 3× Flag tag at the N terminus of the protein. Sind-C* and SpyTag were inserted between amino acids 71 and 74 of the Sindbis virus E2 protein. (B) Surface expression of Sind-C* (positive control (15)) and Sind-SpyTag on 293T cells detected using mouse anti-Flag and Dylight 488-conjugated secondary antibody. As shown in Fig. 3B, Sind-SpyTag protein was displayed on the cell surface with similar efficiency to the positive control Sind-C*.

![FIG 3](image3.png)

**FIG 3** (A) Schematic representation of chimeric Sindbis envelope protein used in this study. Both Sind-C* and Sind-SpyTag contain a 3× Flag tag at the N terminus of the protein. Sind-C* and SpyTag were inserted between amino acids 71 and 74 of the Sindbis virus E2 protein. (B) Surface expression of Sind-C* (positive control (15)) and Sind-SpyTag on 293T cells detected using mouse anti-Flag and Dylight 488-conjugated secondary antibody. As shown in Fig. 3B, Sind-SpyTag protein was displayed on the cell surface with similar efficiency to the positive control Sind-C*.
Next we evaluated the ability of Sind-SpyTag to be incorporated onto lentiviral vectors. Viral supernatants were concentrated 100-fold, separated on a 12% SDS-PAGE gel, and transferred to a polyvinylidene difluoride (PVDF) membrane for Western blot analysis using a mouse anti-Flag or anti-p24 primary antibody and the appropriate secondary antibody. The HIV core p24 antigen is used here as an internal loading control. As shown in Fig. 3C, Sind-SpyTag chimeric envelope protein is incorporated onto the vectors at a level comparable to the positive control Sind-C*. Following the confirmation of virion incorporation of chimeric envelope protein, we determined the ability of DARPin-SpyCatcherΔ to associate with virus-displayed SpyTag and thus confer upon the virus the ability to transduce HER2⁺ cells. Unconcentrated Sind-SpyTag-displaying lentiviral pseudoparticles (Sind-SpyTag-pp, harboring a green fluorescent protein [GFP] reporter gene) were incubated with different concentrations (0 to 40 μM) of DARPin-SpyCatcherΔ or SpyCatcherΔ at room temperature for 1 h. The mixtures were diluted 50-fold in Opti-MEM medium and used to transduce the HER2⁺ ovarian cancer cell line SKOV3. As shown in Fig. 4, only background transduction was observed for naked (0 μM DARPin-SpyCatcherΔ) Sind-SpyTag-pp or those incubated with SpyCatcherΔ (<5% GFP⁺ cells), while significant amounts of GFP⁺ cells were observed in cells transduced by DARPin-SpyCatcherΔ-functionalized virions. The optimum concentration of DARPin-SpyCatcherΔ appeared to be 10 μM, which resulted in >50% GFP⁺ cells. At DARPin-SpyCatcherΔ concentrations higher than 10 μM, DARPin-SpyCatcherΔ molecules that are not bound to virions likely outcompete those incorporated onto the virions for binding to the HER2 receptors on the cell surface, resulting in reduced transduction efficiency. To determine the infectious titer of the in vitro-specificity-reengineered lentivirus, unconcentrated Sind-SpyTag-pp was incubated with 10 μM DARPin-SpyCatcherΔ or SpyCatcherΔ at room temperature for 1 h, and the mixtures were serially diluted and used to transduce SKOV3 cells. The infectious titer was calculated from at least four dilutions that showed linear correlation between the dilution factor and the percentage of GFP⁺ cells. Sind-SpyTag-pp functionalized with DARPin-SpyCatcherΔ efficiently transduced SKOV3 cells with an infectious titer of $5.2 \times 10^6$ IU/ml, >500-fold higher than the naked Sind-SpyTag-pp (<10⁴ IU/ml) or Sind-SpyTag-pp incubated with SpyCatcherΔ (<10⁴ IU/ml) (Fig. 4B). The infectious titer of these DARPin-functionalized lentiviruses is >100-fold and >10-fold higher than the titers of previously reported specificity-reengineered lentiviruses in which DARPin...
proteins were displayed as fusions to an engineered measles virus envelope protein (~10^4 IU/ml) (32) and Nipah virus envelope protein (~10^5 IU/ml) (9), respectively.

To verify that the transduction of DARPin-functionalized virions is HER2 receptor dependent, three human cell lines with different surface expression levels of HER2 were used in a transduction experiment (Fig. 5). The percentage of transduced cells in these cell lines correlated with their cell surface HER2 expression levels. The highest percentage of GFP^+ cells was observed in cells expressing the highest level of HER2 (SKOV3, ~1.3 × 10^5 HER2 molecules per cell [32]), and the smallest amount was observed in the cells with the lowest surface density of HER2 (HT1080, ~2.3 × 10^3 HER2 molecules per cell [32]). The naked virus and virus functionalized with SpyCatcherΔ alone were not able to transduce any of these cells, exhibiting only background levels of GFP^+ cells in the transduced cell population. These results confirmed that the transduction of DARPin-functionalized lentivirus is mediated by HER2 on the cell surface.

To assess the ability of DARPin-functionalized virions to selectively transduce HER2^+ cells in a mixed cell population, we performed a coculture transduction experiment using CHO-HER2-K6, a high-HER2-expressing cell line with an estimated ~2.1 × 10^5 HER2 molecules per cell (32), and CHO-K1 (HER2-negative) cells. Lentivirus pseudotyped with vesicular stomatitis virus (VSV-Gpp), which enters cells via the low-density lipoprotein (LDL) receptor (4) present on both cells, was used as a positive-control lentivirus. CHO-K1 and CHO-HER2-K6 cells, either in isolation or as a 1:1 mixture, were inoculated with VSV-Gpp or DARPin-functionalized Sind-SpyTag-pp. Forty-eight hours later, these cells were analyzed for HER2 expression level and lentiviral transduction (GFP fluorescence) via flow cytometry (Fig. 6). VSV-Gpp transduced CHO-K1 and CHO-HER2-K6 cells with a similarly efficiency, while the naked Sind-SpyTag-pp poorly transduced both cell lines. In contrast, DARPin-displaying Sind-SpyTag-pp showed strong preference for transducing CHO-HER2-K6 cells compared to the HER2-negative CHO-K1 cells. The ability of DARPin-loaded virus to selectively transduce the target cell type points to the potential of this strategy to produce virions capable of delivering genetic cargo specifically to target cells in an in vivo setting.

**Specificity reengineering of lentivirus with MAb-derived CBP.** Antibodies have played a significant role in biotechnology and modern medicine, and a large array of monoclonal antibodies (MAbs) have been developed with ultrahigh affinity and specificity toward diverse targets/receptors. Many MAbs are currently used in the clinic or are in the pipeline for therapeutic applications (33). Unfortunately, to date the advancement in MAB technology has not translated into the creation of target-specific lentiviral vectors for in vivo gene therapy applications, in part due to the lack of an efficient strategy for stable attachment of MAbs to the lentiviral surface. Previously, Irvine Chen's
group exploited protein A to noncovalently anchor MAbs to the lentiviral surface (17, 18, 34, 35). In that strategy, the antibody-Fc domain-specific ZZ domain from protein A was inserted into a binding-deficient, fusion-competent Sindbis virus envelope protein, enabling MAbs to be conjugated onto ZZ-displaying lentiviruses, thus redirecting these vectors to cells displaying the binding partner of the conjugated MAb. Unfortunately, the reversible interaction between the ZZ domain and the Fc of the antibody makes this strategy unsuitable for use in immunocompetent individuals, in which the conjugated antibodies are vulnerable to being displaced by serum immunoglobulins.

To facilitate the use of commercial MAbs for the creation of cell-specific lentiviral vectors, we developed a copper-free click chemistry-mediated conjugation strategy (Fig. 7A). HER2-specific trastuzumab (30) was used as a model MAb. We first digested trastuzumab with IdeS protease (containing a His tag), which cleaves IgG molecules below the hinge region to yield F(\(\text{ab}^\prime\))\(_2\) and Fc fragments (36). The Fc and IdeS were removed using magnetic protein A beads and Ni-nitrilotriacetic acid (NTA) beads, respectively, and the resulting F(\(\text{ab}^\prime\))\(_2\) was mildly reduced to Fab using tris(2-carboxyethyl) phosphine (TCEP). Fab was then reacted with linker sulfo-dibenzocyclooctyl-polyethylene glycol-maleimide (sulfo-DBCO-PEG4-maleimide) to form Fab-DBCO. An unnatural amino acid, p-acetyl phenylalanine (AzF), was recombinantly incorporated into SpyCatcherΔ at the N terminus to form AzF-SpyCatcherΔ, which was reacted with Fab-DBCO to form Fab-SpyCatcherΔ. To evaluate the efficiency of this click chemistry-mediated specificity-reengineering strategy, unconcentrated Sind-SpyTag-pp were incubated with Fab-SpyCatcherΔ at 37°C for 3 h, and the mixture was serially diluted and used to transduce SKOV3 cells (Fig. 7B). Naked Sind-SpyTag-pp was not able to transduce SKOV3 cells. In contrast, Fab-SpyCatcherΔ-functionalized Sind-SpyTag-pp efficiently transduced SKOV3 cells.
with calculated infectious titers of \((2.8 \pm 0.5) \times 10^6\) IU/ml and \((7.6 \pm 1.8) \times 10^6\) IU/ml for virions functionalized with 10 \(\mu\)M and 30 \(\mu\)M Fab-SpyCatcher\(\Delta\), respectively. These infectious titers are similar to that of virions functionalized with 10 \(\mu\)M DARPin-SpyCatcher\(\Delta\) (Fig. 4B). This result demonstrated our ability to direct lentiviral vectors to deliver their genetic cargo to specific cell types using MAb as the CBPs.

**Lentiviruses functionalized via SpyCatcher-SpyTag are resistant to human serum complement.** To be effective in vivo, gene therapy vectors need to remain active even after exposure to the human serum complements, which attack pathogens via multiple pathways (37). To assess the ability of our specificity-reengineered lentiviral vectors to resist serum complement, DARPin-SpyCatcher\(\Delta\)-functionalized Sind-SpyTag-pp were mixed with an equal volume of untreated or complement-inactivated (heat-inactivated) human serum, and the mixtures were incubated at 37\(^\circ\)C for 1 h, diluted 50-fold in Opti-MEM medium, and used to transduce SKOV3 cells. Similar infectivities were observed in virions incubated with untreated and complement-
inactivated human serum (Fig. 8), indicating that lentiviral vectors surface modified via SpyCatcher-SpyTag chemistry are compatible with human serum complement. This result is consistent with the observation that the Sindbis virus envelope proteins are resistant to human serum complement (35). This low serum sensitivity is in contrast to lentiviruses retargeted through (i) display of a CBP as fusion to the measles virus envelope protein (32, 38, 39) (relevant mainly in measles virus vaccine-naive populations) and (ii) conjugation of cell surface receptor-specific antibodies via noncovalent interaction between the antibody Fc domain and the Fc domain-specific ZZ domain from protein A (17, 18, 34, 35). In the latter method of specificity reengineering, the displayed antibodies are at risk of being displaced by circulating serum immunoglobulins in immunocompetent individuals (40).

**DISCUSSION**

The progress of gene therapy has been hampered by the absence of a lentiviral vector that can be robustly and reproducibly functionalized with a cell-homing functionality to mediate specific delivery of therapeutic genes to diseased cells. Existing strategies to reengineer the cell-type specificity of viral vectors have suffered from challenges, including (i) difficulties in achieving a reproducibly high virion incorporation level (for example, when attempting to fuse a cell receptor-binding protein to viral envelope protein [13]), (ii) a lack of in vivo compatibility, as seen in approaches employing protein A for anchoring cell-specific antibodies (17, 18) and noncovalent bridge proteins for linking a cell-binding protein with a protein expressed on the lentiviral surface (15), and (iii) a very limited repertoire of cell types that can be targeted (e.g., when pseudotyping the lentiviral vectors with envelope proteins from viruses that have a natural tropism for the cell type of interest [5–7]).

In this study, we describe a simple approach to retarget lentiviral vectors that has the potential to greatly expand the repertoire of cell types that can be specifically targeted by lentiviral vectors. Specifically, we employed an isopeptide bond-forming protein-peptide pair—the N-terminal fragment (Spycatcher) and C-terminal fragment (SpyTag) of the collagen adhesion domain (CnAB2) from the fibronectin binding protein (FbaB) in *Streptococcus pyogenes* (19–22)—to robustly conjugate a CBP to the lentiviral surface, thus yielding stable cell-type-specific lentiviral vectors. The SpyTag is inserted into a binding-deficient and fusion-competent Sindbis virus envelope protein and displayed on the surface of pseudotyped lentiviral particles (Sind-SpyTag-pp). The surface-displayed SpyTag is used as the anchorage site for a cell-binding protein (CBP) associated with SpyCatcher. Entry of enveloped viruses into cells requires two major steps, each mediated by a different viral protein or protein domain: (i) virus-cell
attachment and (ii) fusion of the viral and cellular membranes. For many viruses, abolishment of viral attachment through mutation/deletion of the attachment function does not impair the fusion function. Viruses with an abolished wild-type attachment function can potentially be retargeted to new cell types through the incorporation of cell-specific CBPs. Using a HER2-binding DARPin as our model CBP, we first created the fusion protein DARPin-SpyCatcherΔ. SpyCatcherΔ is a truncated version of SpyCatcher that lacks 21 and 14 residues at the N- and C-termini, respectively, and was used in this work because the full-length SpyCatcher was found to interact with an undefined receptor on SKOV3 cells (Fig. S1). SpyCatcherΔ was able to efficiently form an isopeptide bond with SpyTag (Fig. 2) but exhibited significantly reduced ability to nonspecifically interact with SKOV3 cells. Unconcentrated supernatant containing Sind-SpyTag-pp functionalized with DARPin-SpyCatcherΔ efficiently transduced HER2+ SKOV3 cells with an infectious titer of $5.2 \times 10^6$ IU/ml, which is $>500$-fold higher than the naked Sind-SpyTag-pp (<$10^4$ IU/ml) or Sind-SpyTag-pp functionalized with only SpyCatcherΔ (<$10^4$ IU/ml).

A slightly higher percentage of GFP+ cells was observed in HER2- CHO-K1 cells transduced by DARPin-SpyCatcherΔ-functionalized virions (4.9%) than the naked virions (1.4%) (Fig. 7). Since the DARPin used in this study is highly specific to HER2 and has previously been used to create HER2-specific pseudotyped measles virus (32) and Nipah virus (9) with very low background transduction of nontarget cells, we suspect that the slightly higher transduction of the CHO-K1 cells by DARPin-functionalized virions is likely due to interaction between SpyCatcherΔ and another undefined cell surface receptor on the hamster-derived CHO-K1 cells. Ongoing work aims to further reduce the background transduction of nontargeting cells.

To expand the repertoire of cell types that can be specifically transduced, a click chemistry-based strategy was developed to redirect lentiviruses to specific cell types using the Fab fragments of receptor-specific MAbs. Using the Fab fragments derived from the HER2-specific MAB trastuzumab as a model CBP, we demonstrated that Sind-SpyTag-pp could be redirected to HER2-displaying SKOV3 cells, yielding a high infectious titer of $2.8 \times 10^6$ IU/ml. The ability to covalently conjugate MAB-derived CBP to lentiviruses opens the door to the potential immediate use of a plethora of existing cell receptor-specific MAbs for the creation of cell-type-specific lentiviruses, greatly expanding the cell types that can be specifically targeted for lentiviral gene delivery.

In summary, this work reports a novel in vitro method for functionalizing the surface of lentiviral vectors that exploits an isopeptide bond-forming protein-peptide pair: SpyTag-SpyCatcher. This approach should facilitate the creation of lentiviral vectors that are able to specifically deliver their genetic cargo to a wide range of different cell types, greatly broadening the potential of lentiviral vectors as gene delivery vehicles for functional genomics and gene therapy applications.

**MATERIALS AND METHODS**

**Infection assays.** Unconcentrated supernatants containing Sind-SpyTag-pp (harboring a GFP reporter gene) were incubated with the indicated concentrations of purified DARPin-SpyCatcherΔ, SpyCatcherΔ, or Fab-SpyCatcherΔ at room temperature for 1 h to promote incorporation of the SpyCatcher constructs onto the virion surface. The mixture was then diluted 50-fold in Opti-MEM medium and used to transduce cells in 48-well plates ($3.3 \times 10^4$ cells/well) via spinoculation for 1 h at 300 × g and 25°C followed by incubation at 37°C for 2 h. The cells were washed to remove unbound viruses and incubated at 37°C in 5% CO2. Positive-control lentiviruses were pseudotyped with vesicular stomatitis virus glycoprotein (VSV-G) and contained the same GFP reporter gene. VSV-Gpp were diluted 50-fold in Opti-MEM medium before use. The percentage of transduced cells (GFP+) in each well was quantified 48 h later using a BD FACSscan flow cytometer (BD Biosciences; San Jose, CA). For virus titer determination, functionalized virions were serially diluted before being used for transduction. The number of infectious units per milliliter was calculated from at least three dilutions that showed a linear correlation between the dilution factor and the percentage of GFP-positive cells using the equation 

$$MOI = -\ln(1 - \% \text{ of GFP}^+ \text{ cells/100}$$

where MOI is the multiplicity of infection.

For the coculture transduction experiment, the cells were stained with anti-HER2-phycoerythrin (PE) (BD Biosciences; San Jose, CA) before being analyzed by flow cytometry.

**Conjugation of Fab to AzF-SpyCatcherΔ.** Trastuzumab (1 mg/ml in phosphate-buffered saline [PBS]) was first digested with the enzyme IdeS (containing a 6× His tag at 1% [wt/wt]) at 37°C for 1 h to convert MAb to F(ab′)2. The IdeS and the generated Fc fragments were removed via exposure to...
Ni-NTA agarose beads (Qiagen) and protein A-coated magnetic beads (Pierce), respectively. The resulting Fab\(^{-}\) fragments were reduced to Fab\(^{'}\) by incubation with 5 mM tris(2-carboxyethyl)phosphine (TCEP) at 37°C for 30 min, desalted using a Bio-Spin 6 column to remove TCEP, and then reacted with the linker sulfo-DBCO-PEG\(_{2}\)-maleimide (10 mM; Click Chemistry Tools) in PBS at 4°C for 1 h to form Fab-DBCO. Excess unreacted linker molecules were removed by passage of the reaction mixture through another Bio-Spin 6 column. The concentration of the Fab-SpyCatcherΔ was determined using the bicinchoninic acid (BCA) assay kit (Thermo Fisher Scientific, Waltham, MA).

Additional materials and methods are provided in Text S1 in the supplemental material. The protein sequences for all constructs are provided in Text S2 in the supplemental material.

**SUPPLEMENTAL MATERIAL**

Supplemental material for this article may be found at https://doi.org/10.1128/mBio.01860-17.

**TEXT S1**, PDF file, 0.1 MB.

**TEXT S2**, PDF file, 0.1 MB.

**FIG S1**, PDF file, 0.1 MB.

**FIG S2**, PDF file, 0.1 MB.

**ACKNOWLEDGMENTS**

Plasmids encoding DARPin.9.26 and Spycatcher were provided by Andreas Pluckthun (University of Zurich, Switzerland) and Mark Howarth (University of Oxford, United Kingdom), respectively. Plasmids encoding HIV Gag-Pol and vesicular stomatitis virus glycoprotein (VSV-G) were provided by Charles Rice (Rockefeller University, NY). We are grateful for Karuppiah Chockalingam for critical review of the manuscript.

We would like to gratefully acknowledge the financial support from the National Science Foundation (CBET no. 1461705) and the National Institutes of Health (DP2OD024146).

**REFERENCES**

1. Günzburg WH, Fleuchaus A, Saller R, Salmons B. 1996. Retroviral vector targeting for gene therapy. Cytokines Mol Ther 2:177–184.

2. Kotterman MA, Chalberg TW, Schaffer DV. 2015. Viral vectors for gene therapy: translational and clinical outlook. Annu Rev Biomed Eng 17: 63–89. https://doi.org/10.1146/annurev-bioeng-071813-104938.

3. Fisher A, Stark A. 2017. FDA approval brings first gene therapy to the United States. https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm574058.htm.

4. Finkelstein D, Werman A, Novick D, Barak S, Rubinstein M. 2013. LDL receptor and its family members serve as the cellular receptors for vesicular stomatitis virus. Proc Natl Acad Sci U S A 110:7306–7311. https://doi.org/10.1073/pnas.1214411110.

5. Girard-Gagnepain A, Amirache F, Costa C, Lévy C, Frecha C, Fusil F, Nègre D, Lavillette D, Cosset FL, Verhoeyen E. 2014. Baboon envelope pseudotyped LVs outperform VSV-G-LVs for gene transfer into early-cytokine-stimulated and resting HSCs. Blood 124:1221–1231. https://doi.org/10.1182/blood-2014-02-558163.

6. Bartosch B, Cosset FL. 2009. Studying HCV cell entry with HCV pseudotypes. Methods Mol Biol 510:279–293. https://doi.org/10.1007/978-1-59745-394-3_21.

7. Palomares K, Vigant F, Van Handel B, Pernet O, Chikere K, Hong P, Sherman SP, Lee B. 2013. Nipah virus envelope-pseudotyped lentiviruses efficiently target ephrinB2-positive stem cell populations in vitro and in vivo. J Virol 87:2094–2108. https://doi.org/10.1128/JVI.02032-12.

8. Funke S, Maisner A, Mühlbach MD, Koehler U, Grez M, Cattaneo R, Buchholz CJ. 2008. Targeted cell entry of lentiviral vectors. Mol Ther 16:1427–1436. https://doi.org/10.1038/mt.2008.128.

9. Bender RR, Muth A, Schneider IC, Friedel T, Hartmann J, Plückthun A, Maisner A, Buchholz CJ. 2016. Receptor-targeted Nipah virus glycoproteins improve cell-type-selective gene delivery and reveal a preference for membrane-proximal cell attachment. PLoS Pathog 12:e1005641. https://doi.org/10.1371/journal.ppat.1005641.

10. Witting SR, Vallanda P, Gamble AL. 2013. Characterization of a third generation lentiviral vector pseudotyped with Nipah virus envelope proteins for endothelial cell transduction. Gene Ther 20:997–1005. https://doi.org/10.1038/gt.2013.23.

11. Snitkovsky S, Young JA. 1998. Cell-specific viral targeting mediated by a soluble retroviral receptor-ligand fusion protein. Proc Natl Acad Sci U S A 95:7063–7068. https://doi.org/10.1073/pnas.95.12.7063.

12. Boerger AL, Snitkovsky S, Young JA. 1999. Retroviral vectors preloaded with a viral receptor-bridge protein are targeted to specific cell types. Proc Natl Acad Sci U S A 96:9867–9872. https://doi.org/10.1073/pnas.96.17.9867.

13. Buchholz CJ, Friedel T, Bünning H. 2015. Surface-engineered viral vectors for selective and cell type-specific gene delivery. Trends Biotechnol 33:777–790. https://doi.org/10.1016/j.tibtech.2015.09.008.

14. Friedel T, Hanisch LJ, Muth A, Honegger A, Abken H, Plückthun A, Buchholz CJ, Schneider IC. 2015. Receptor-targeted lentiviral vectors are exceptionally sensitive toward the biophysical properties of the displayed single-chain Fv. Protein Eng Des Sel 28:93–106. https://doi.org/10.1093/protein/gzv005.

15. Chamoun-Emanueli AM, Wright G, Roger S, III, Münch RC, Buchholz CJ, Chen Z. 2015. In vitro incorporation of a cell-binding protein to a lentiviral vector using an engineered split intein enables targeted delivery of genetic cargo. Biotechnol Bioeng 112:2611–2617. https://doi.org/10.1002/bit.25685.

16. Ramirez M, Valdés N, Guan D, Chen Z. 2013. Engineering split intein Dnae from Nostoc punctiforme for rapid protein purification. Protein Eng Des Sel 26:215–223. https://doi.org/10.1093/protein/gzs097.

17. Morizono K, Xie Y, Ringps GE, Johnson M, Nassanian H, Lee B, Wu L, Chen IS. 2005. Lentiviral vector retargeting to P-glycoprotein on metastatic melanoma through intravenous injection. Nat Med 11:346–352. https://doi.org/10.1038/nm1192.

18. Morizono K, Bristol G, Xie YM, Kung SK, Chen IS. 2001. Antibody-directed tumor targeting of retroviral vectors via cell surface antigens. J Virol 75: 8016–8020. https://doi.org/10.1128/JVI.75.17.8016-8020.2001.

19. Kang HJ, Coulibaly F, Clow F, Proft T, Baker EN. 2007. Stabilizing isopep-
tide bonds revealed in Gram-positive bacterial pilus structure. Science 318:1625–1628. https://doi.org/10.1126/science.1145806.

20. Zakeri B, Howarth M. 2010. Spontaneous intermolecular amide bond formation between side chains for irreversible peptide targeting. J Am Chem Soc 132:4526–4527. https://doi.org/10.1021/ja910795a.

21. Zakeri B, Fierer JO, Celik E, Chittock EC, Schwarz-Linek U, Moy VT, Howarth M. 2012. Peptide tag forming a rapid covalent bond to a protein, through engineering a bacterial adhesin. Proc Natl Acad Sci U S A 109:E690–E697. https://doi.org/10.1073/pnas.1115485109.

22. Li L, Fierer JO, Rapoport TA, Howarth M, Rapoport TA, Howarth M. 2014. Structural analysis and optimization of the covalent association between SpyCatcher and a peptide tag. J Mol Biol 426:309–317. https://doi.org/10.1016/j.jmb.2013.10.021.

23. Hagan RM, Björnsson R, McMahon SA, Schomburg B, Braithwaite V, Bühl M, Naismith JH, Schwarz-Linek U. 2010. NMR spectroscopic and theoretical analysis of a spontaneously formed Lys–Asp isopeptide bond. Angew Chem Int Ed Engl 49:8421–8425. https://doi.org/10.1002/anie.201004340.

24. Reddington SC, Howarth M. 2015. Secrets of a covalent interaction for biomaterials and biotechnology: SpyTag and SpyCatcher. Curr Opin Chem Biol 29:94–99. https://doi.org/10.1016/j.cbpa.2015.10.002.

25. Zhang WB, Sun F, Tirrell DA, Arnold FH. 2013. Controlling macromolecular topology with genetically encoded SpyTag-SpyCatcher chemistry. J Am Chem Soc 135:13988–13997. https://doi.org/10.1021/ja4076452.

26. Gao X, Fang J, Xue B, Fu L, Li H. 2016. Engineering protein hydrogels using SpyCatcher-SpyTag chemistry. Biomacromolecules 17:2812–2819. https://doi.org/10.1021/acs.biomac.6b00566.

27. Sun F, Zhang WB, Mahdaví A, Arnold FH, Tirrell DA. 2014. Synthesis of bioactive protein hydrogels by genetically encoded SpyTag-SpyCatcher chemistry. Proc Natl Acad Sci U S A 111:11269–11274. https://doi.org/10.1073/pnas.1401291111.

28. Brune KD, Leneghan DB, Brian U, Ishizuka AS, Bachmann MF, Draper SJ, Biswas S, Howarth M. 2016. Plug-and-display: decoration of virus-like particles via isopeptide bonds for modular immunization. Sci Rep 6:19234. https://doi.org/10.1038/srep19234.

29. Zahnd C, Wyler E, Schwenk JM, Steiner D, Lawrence MC, McKern NM, Pecorari F, Ward CW, Joos TO, Plückthun A. 2007. A designed ankyrin repeat protein evolved to picomolar affinity to Her2. J Mol Biol 369:1015–1028. https://doi.org/10.1016/j.jmb.2007.03.028.

30. Sliwkowski MX, Lofgren JA, Lewis GD, Hotaling TE, Fendly BM, Fox JA. 1999. Nonclinical studies addressing the mechanism of action of trastuzumab (Herceptin). Semin Oncol 26:60–70.

31. Steiner D, Forrer P, Plückthun A. 2008. Efficient selection of DARPin vectors with sub-nanomolar affinities using SRP phage display. J Mol Biol 382:1211–1227. https://doi.org/10.1016/j.jmb.2008.07.085.

32. Münch RC, Mühlebach MD, Schaser T, Kneissl S, Jost C, Plückthun A, Cichutek K, Buchholz CJ. 2011. DARPin: an efficient targeting domain for lentiviral vectors. Mol Ther 19:686–693. https://doi.org/10.1038/mt.2010.298.

33. Wold ED, Smider VV, Felding BH. 2016. Antibody therapeutics in oncology. Immunotherapy 2:108. https://doi.org/10.4172/2471-9552.1000108.

34. Pariente N, Morizono K, Virk MS, Petrigliano FA, Reiter RE, Lieberman JR, Chen IS. 2007. A novel dual-targeted lentiviral vector leads to specific transduction of prostate cancer bone metastases in vivo after systemic administration. Mol Ther 15:1973–1981. https://doi.org/10.1038/sj.mt.3000271.

35. Morizono K, Ku A, Xie Y, Harui A, Kung SK, Roth MD, Lee B, Chen IS. 2010. Redirecting lentiviral vectors pseudotyped with Sindbis virus-derived envelope proteins to DC-SIGN by modification of N-linked glycans of envelope proteins. J Virol 84:6923–6934. https://doi.org/10.1128/JVI.00435-10.

36. Ryan MH, Petrone D, Nemeth JF, Barnathan E, Björck L, Jordan RE. 2008. Proteolysis of purified IgGs by human and bacterial enzymes in vitro and the detection of specific proteolytic fragments of endogenous IgG in rheumatoid synovial fluid. Mol Immunol 45:1837–1846. https://doi.org/10.1016/j.molimm.2007.10.043.

37. Schauber-Plewa C, Simmons A, Tuerk MJ, Pacheco CD, Veres G. 2005. Complement regulatory proteins are incorporated into lentiviral vectors and protect particles against complement inactivation. Gene Ther 12:238–245. https://doi.org/10.1038/sj.gt.3302399.

38. Kneissl S, Abel T, Rasbach A, Brynza J, Schneider-Schaullies J, Buchholz CJ. 2012. Measles virus glycoprotein-based lentiviral targeting vectors that avoid neutralizing antibodies. PLoS One 7:e46667. https://doi.org/10.1371/journal.pone.0046667.

39. Friedrich K, Hanauer JR, Prüfer S, Münch RC, Völker I, Filippis C, Jost C, Hanksch MM, Cattaneo R, Peng KW, Plückthun A, Buchholz CJ, Cichutek K, Mühlebach MD. 2013. DARPin-targeting of measles virus: unique bispecificity, effective oncolyisis, and enhanced safety. Mol Ther 21:849–859. https://doi.org/10.1038/mt.2013.16.

40. Morizono K, Pariente N, Xie Y, Chen IS. 2009. Redirecting lentiviral vectors by insertion of integrin-targeting peptides into envelope proteins. J Gene Med 11:298–309. https://doi.org/10.1002/jmg.20476.

41. Kasaraneni et al. November/December 2017 Volume 8 Issue 6 e01860-17 mbio.asm.org 12